

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07H 21/02, 21/04, C12Q 1/68, A61K 48/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/15334</b> <b>(43) International Publication Date:</b> 8 June 1995 (08.06.95)
<b>(21) International Application Number:</b> PCT/US94/13823 <b>(22) International Filing Date:</b> 30 November 1994 (30.11.94) <b>(30) Priority Data:</b> 08/160,088 30 November 1993 (30.11.93) US 08/314,598 27 September 1994 (27.09.94) US <b>(71) Applicant:</b> CALIFORNIA PACIFIC MEDICAL CENTER RESEARCH INSTITUTE [US/US]; 2330 Clay Street, San Francisco, CA 94115 (US). <b>(72) Inventors:</b> SCHOTT, David, R.; 538 41st Street, Richmond, CA 94805 (US). SMITH, Helene, S.; 4270 Army Street, San Francisco, CA 94131 (US). CHANG, Julielani; 409 Heron Place, Davis, CA 95616 (US). <b>(74) Agents:</b> SUYAT, Reginald, J. et al.; Heller, Ehrman, White & McAuliffe, 333 Bush Street, San Francisco, CA 94104-2878 (US).		<b>(81) Designated States:</b> AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> cDNA PROBE FOR BREAST CANCER DIAGNOSIS AND TREATMENT  <b>(57) Abstract</b>  Some cDNA probes cloned from an mRNA coded for by an isolated gene (designated Brush-1) located at 13q12-q13 that is useful in diagnosis and treatment of breast cancer are disclosed. The probe provides a means for detection of premalignant mammary cells and early detection of breast cancer. It is also useful in designing therapeutic treatments for these conditions by traditional pharmaceutical methods or gene therapy.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## CDNA PROBE FOR BREAST CANCER DIAGNOSIS AND TREATMENT

FIELD OF THE INVENTION

The invention herein was made with government support under contract 5P01 CA 44768-09  
5 with the National Cancer Institute. The federal government may have certain rights in this invention.

BACKGROUND OF THE INVENTION

Breast cancer is one of the most common malignancies found among women above the age of 35  
10 and results in thousands of deaths in the United States each year. Current treatments, including radiation, chemotherapy and mastectomy, have been successful in halting or slowing the disease's progress, but these known treatments have many  
15 undesirable side effects of their own.

Early detection of the disease is essential to a positive prognosis for breast cancer treatment. Frequently, by the time a tumor is detected, the disease has already progressed to the point where  
20 successful treatment by known methods is difficult or impossible.

Research has produced some new compounds and methods for diagnosis and treatment of certain

types of cancerous conditions. U.S. Patent No. 5,262,528, for instance, is directed to a cDNA probe differentiating normal and cancerous tissues and U.S. Patent No. 4,942,123 is directed to a method of  
5 diagnosis of retinoblastoma and "involved cancers", said to include breast cancer.

Inactivation of tumor suppressor genes may play an important role in human cancers, including breast cancer. See Ponder, B., *Nature (Lond.)* 335:  
10 400-402 (1988); Sager, R., *Science* 246: 1406-1412 (1989). This is thought to occur by the inactivation of one allele and the subsequent loss or replacement of the other allele contained on a chromosomal segment. Several localized regions have been  
15 implicated by the coincidence of their loss in various breast tumors. These include the short arms of chromosomes 3, 17 and 18 and sites on the long arms of chromosomes 1, 13 and 22. See Sato, T., et al., *Cancer Res.* 50: 7184-7189 (1990); Devilee, p.,  
20 et al., *Int. J. Cancer* 47: 817-821 (1991); Chen, L-C, et al., *J. Natl. Cancer Inst.* 84: 506-510 (1992). Of particular interest is the chromosome 13q region which shows relatively frequent loss of heterozygosity (LOH) in breast tumors suggesting an  
25 important role in breast cancer initiation and/or progression. See Lundberg, C., et al., *Proc. Natl. Acad. Sci. USA* 84: 2372-2376 (1987); Devilee, p., et al., *Genomics* 5: 554-560 (1989). Most of these studies have focussed on the q14 region which  
30 contains the retinoblastoma (RB1) gene located at 13q14.2. RB1, the gene involved in heredity and sporadic retinoblastoma, was also the first gene identified and characterized as a tumor suppressor gene. See Stanbridge, E.J., *Functional evidence for*  
35 *human tumour suppressor genes: chromosome and molecular genetic studies*, in GENETIC SURVEYS 12:

- 3 -

TUMOUR SUPPRESSOR GENES, THE CELL CYCLE AND CANCER 5-  
24 (1992)). The relationship between RB1 and breast  
cancer, however, is not clear. Subsequent studies  
have shown that the LOH for RB1 in breast cancer is  
5 not correlated with the loss of RB1 gene expression.  
See Borg, A., et al., *Cancer Res.* 52: 2991-2994  
(1992). In addition, LOH in the region next to RB1  
has been found in human breast carcinoma while the  
RB1 gene itself did not show such a genetic change.  
10 See Devilee, p., et al., *Genomics* 5: 554-560 (1989).  
Hence, upon closer re-examination of this region, the  
finding has been made that RB1 expression, at least  
for mRNA, apparently is not affected by LOH in the  
region which includes RB1. Instead, a proximal gene  
15 demonstrates the expected pattern of a tumor  
suppressor gene for breast cancer.

The gene cloned and sequenced as described  
herein, *Brush-1*, may represent yet another member of  
a new class of tumor suppressor genes that function  
20 directly as RNA or as the RNA component of a  
ribonucleoprotein as has been described for the H19  
gene (Brannan et al., 1990, *Mol. Cell. Biol.* 10:29  
Hao et al., 1993, *Nature* 365:764). Both *Brush-1* and  
H19 are expressed as a polyadenlyated RNA; are  
25 expressed at higher levels in fetal as compared to  
adult tissues; contain multiple small open reading  
frames; are both conserved in the monkey genome  
(shown by zoo blot hybridization); are located in  
regions of frequent LOH; and show loss of RNA  
30 expression in tumors demonstrating this LOH.

Known applications of sequenced genes  
include use of the sequences or of RNA or amino acid  
sequences derived therefrom for diagnosis or  
treatment of the corresponding disease. Accordingly,  
35 it is useful for the diagnosis and treatment of

- 4 -

breast cancer to isolate and further characterize this gene in the region next to RB1.

An object of the present invention is to provide a cDNA probe derived from this gene  
5 (designated Brush-1) useful in diagnosis and treatment of breast cancer.

Additional objects and advantages of the invention will be set forth in the description of the preferred embodiments which follows, and in part will  
10 be obvious from the description, or will be learned by practice of the invention.

#### SUMMARY OF THE INVENTION

The present invention is directed to a novel DNA sequence complementary to an mRNA coded for  
15 by an isolated gene (designated Brush-1) located at 13q12-q13 that is useful as a probe in diagnosis and treatment of breast cancer. The probe provides a means for detection of premalignant mammary cells and early detection of breast cancer. It is also useful  
20 in designing therapeutic treatments for these conditions by traditional pharmaceutical methods or gene therapy.

#### BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings are incorporated  
25 in and constitute a part of the specification.

Figure 1 depicts an autoradiogram of a Northern blot analysis of Brush-1 mRNA. 10 µg per

lane of polyadenylated RNA were analyzed by probing with the 1.5 kb Brush-1 cDNA representing the most 3'-region.

Figure 2 depicts an autoradiogram of a RT-PCR Analysis. Products from RT-PCR run on 1% agarose gel and stained with ethidium bromide. RNA source: lanes 2-4, CAMA1; 5-7, DU4475; 8-10, G94; 11-13, MDA468; Amplimers: lanes 2,5,8 & 11, Brush-1; lanes 3,6,9,12, RBI; lanes 4,7,10,13,  $\beta$ -Actin; pGEM marker: lanes 1 and 14.

Figure 3 depicts the position of Brush-1 cDNA clones relative to the 4.7kb mRNA.

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

The following describes the characterization of the gene (designated Brush-1) localized to the 13q region proximal to RB1 that is differentially expressed in normal versus tumor mammary epithelial cells and the isolation and derivation of mRNA and cDNA sequences therefrom. This description does not limit the invention and those of ordinary skill in the art will recognize that many variations on this method can be used with equivalent efficacy produce a cDNA probe.

The growth conditions for the various breast cancer cell lines and normal cells isolated from reduction mammoplasties are described in Smith, H.S., *In vitro models in human breast cancer in BREAST DISEASES*, 2ND EDITION 181-189 (J.R. Harris, et al., eds., 1991). Human breast primary tumor samples

- 6 -

and paired normal skin tissues were collected from 76 individuals. Tumor samples were dissected to remove most of the normal tissue, and stored in liquid nitrogen until use. If the skin tissues are too small to isolate sufficient DNA for analysis, cultured skin fibroblasts from the same patient may be used to extract DNA.

DNA isolation was performed as described by Kallioniemi, A., et al., *Cytogenet. Cell Genet.* 60: 190-193 (1992), incorporated by reference herein. Total RNA was isolated from both tissue culture cells and primary tumors using the Ultraspec™ RNA method (Biotecx Laboratories, Inc., TX). Final RNA pellets were resuspended in DEPC water and then stored at -70°C. Procedures for polyadenylated mRNA selection and subsequent Northern analysis are described in Sambrook, J., Fritsch, E.F. & Maniatis, T., *MOLECULAR CLONING: A LABORATORY MANUAL* (1992).

Single stranded cDNA was synthesized by oligo(dT) priming (0.5 µg) from 3µg of total RNA using 20U of M-MLV Reverse Transcriptase (RT) (Gibco, BRL) in a final volume of 20 µL. The RT enzyme was inactivated by incubation at 70°C for 10 minutes and the product was diluted to 200 µl. A 5µl aliquot of cDNA was used directly for each PCR amplification. Specific amplification for each of three different mRNA species was achieved using sequence specific primers. Amplification primers for the β-Actin gene were obtained from Clontech Laboratories (Palo Alto, CA) and consisted of the following sequences; 5'-ATGGATGATGATATCGCCGCG-3' and 5'-CTAGAAGCATTTGCGGTGGACGATGGAGGGGCC-3'. The mRNA from the RB1 gene was amplified using the previously described primers: C3-5, 5'-TACTGCAAATGCAGAGACACA-3' and C4-3, 5'-TGTTCCCTCCAGGAATCCGTA-3' (Mori, N., et al., *Oncogene* 5:



- 7 -

1713-1717 (1990)). Both of these primer pairs were chosen to span intron sequences in order to ensure that the resulting products were not due to amplification from genomic DNA. Brush-1 mRNA was amplified using primers homologous to regions within the Brush-1 sequence: 5'-TTAGTGCGCACTTTATTC-3' and 5'-CATCAGTGTAGCCA AGC-3'. This primer pair does not span an intron and Reverse Transcription-Polymerase Chain Reaction (RT-PCR) was conducted both with and without the RT enzyme to assure that results did not reflect DNA contamination. The PCR reaction mixture (50  $\mu$ L final vol.) consisted of: template cDNA, 1.5 mM  $MgCl_2$ , 200  $\mu$ M dNTPs (each), 20 pmol of each primer pair and 1 U of Taq DNA polymerase (Promega). The entire PCR mixture was heated to 95°C for 3 min to assure complete dissociation of the template sequences and then subject to 35 cycles of amplification under the following conditions: 95°C for 30 s, 50°C for 30 s and 72°C for 3 min with a final extension at 72°C for 10 min. The PCR products were separated on a 1% agarose gel and ethidium bromide stained for visualization.

LOH analyses used DNA from both tumors and normal tissues. DNA aliquots (40 ng) were used as templates for PCR amplification of polymorphic markers (Weissenbach, J., et al., *Nature (Lond.)*, 359: 794-801 (1992)) using primers specific for the D13S219 region at 13q13 (Research Genetics, Huntsville, AL). These primers flank a CA repeat polymorphism localized to chromosome 13q13, proximal to RB1. Primers for the RB1 gene (Brandt, B., et al., *Am. J. Hum. Genet.* 51: 1450-1451 (1992) flank a variable number terminal repeat (VNTR) which is highly polymorphic. PCR conditions used for the LOH analyses at both the D13S219 and RB1 sites are those described for the RT-PCR analyses with the following

- 8 -

modifications: Cycle conditions for D13S219 were 35 cycles of amplification under the following conditions: 94°C for 30 s, 56°C for 30 s and 72°C for 30 s with a final extension at 72°C for 10 min.

5 Cycle conditions for RB1 VNTR were 35 cycles of amplification under the following conditions: 95°C for 45 s, 53°C for 25 s and 72°C for 2 min. with a final extension at 72°C for 10 min. All PCR products were separated by electrophoresis on a 6%  
10 polyacrylamide gel and stained with ethidium bromide for visualization. PCR products from amplification of paired normal and tumor DNA from the same individual were compared to determine first, if the individual was heterozygous at the tested site and  
15 second, whether one of the alleles had been lost indicating that there had been a loss of heterozygosity (LOH).

The 4.11N 1.5 kb cDNA fragment (see Figure 3) was subcloned into the Bluescript plasmid  
20 (Stratagene). Both strands of the cDNA fragment were sequenced using the Sequenase 2.0 system of dideoxynucleotide chain termination (US Biochemicals). The sequence was analyzed using the Eugene (Baylor College of Medicine) sequence analysis  
25 program. The Brush-1 cDNA fragment was labeled with <sup>32</sup>P-dCTP using the Multiprime labeling system (Amersham). This probe was used to screen a total of 5 X 10<sup>5</sup> independent clones from an EMBL-3 human placental genomic library (Clontech, Palo Alto, CA).  
30 Two genomic clones corresponding to this cDNA were isolated.

One additional cDNA clone, designated 4.11T, was isolated by using the 4.11N as a probe for screening a cDNA library derived from breast tumor  
35 mRNA. Two other clones, designated 4.11K1 and 4.11K2 were isolated, and the relative positions of the

- 9 -

clones within the mRNA were determined using the RACE method as described by Frohman, et al., *Proc. Natl. Acad. Sci. USA* **85**: 8998-9002 (1988) (see Figure 3).

The Northern blots were prepared as described by Sambrook, J., Fritsch, E.F. & Maniatis, T., *MOLECULAR CLONING: A LABORATORY MANUAL* (1992) using 10 ug of poly-A<sup>+</sup> selected RNA. These were probed using the radioactively labelled cDNA fragment described above. The EMBL-3 genomic DNA clones described above served as Brush-1 templates for the FISH analysis. The RB probe and methods used for the FISH analysis are previously described in Kallioniemi, A., et al., *Cytogenet. Cell Genet.* **60**: 190-193 (1992).

The Brush-1 mRNA was initially detected on Northern gels of normal breast epithelium RNA at levels comparable to those seen for RB1 (see Figure 1). Brush-1 codes for a single 4.7 kb mRNA. An RT-PCR approach was used for a survey of breast cancer cell lines in order to compare expression for Brush-1 with RB1 (which also codes for a 4.7 kb mRNA). An example of this is seen in Figure 2 where RNAs from normal breast epithelium and three breast cancer cell lines were analyzed with this RT-PCR technique. After the initial RT step, three different amplicon sets were used to analyze each of the newly synthesized cDNAs. The first amplicon set was specific to the Brush-1 mRNA, the second was specific to the RB1 mRNA and the third, for  $\beta$ -Actin, served as a control. The expected sizes of the amplified DNA products were 592, 539 and 1126 base pairs for Brush-1, RB1 and  $\beta$ -Actin, respectively. Two of the breast cancer cell lines (CAMA1 and DU4475) have negligible expression for Brush-1 whereas both the normal breast epithelium (G94) and another breast cancer cell line

- 10 -

(MDA468) express high levels of the Brush-1 mRNA. All four types of breast cells have high levels of  $\beta$ -Actin expression and only DU4475 cells do not express RB1.

5 This survey was extended to additional samples of both normal breast epithelium and breast cancer cell lines. The results are shown in Table 1.

Table 1

10	<u>Types of Specimen</u>	<u>Expression of Brush-1<sup>a</sup></u>	<u>Expression of RB1<sup>a</sup></u>	<u>LOH at 13q13- q14<sup>b</sup></u>
	<b>A. Primary Breast Tumors</b>			
	B200	+	+	-
	B201	+	+	-
15	B212	+	+	-
	B381	+	+	-
	B317	-	+	+
	B349	-	+	+
	B398	-	+	+
20	B406	-	+	+
	<b>B. Cells in culture</b>			
	<b>1. Normal Mammary Epithelium</b>			
25	337EA	+	+	
	998E	+	+	
	1130E	+	+	
	G61E	+	+	
	G94E	+	+	
30	<b>2. Breast Cancer Cell Lines</b>			
	BT20	+	+	
	MCF7	+	+	
	BT474	+	+	
35	MDA157	+	+	
	MDA231	+	+	
	MDA468	+	+	
	MPE600	+	+	
	CAMA1	-	+	
40	MDA435	-	+	

MDA134	-	+
SKBR3	-	+
UACC812	-	+
DU4475	+/-	-

- 5 a Detection of specific mRNAs by RT-PCR: (+) = presence; (-) = absence, (+/-) = greatly reduced levels.  
 b Detection of LOH: (+) = LOH for the region; (-) = no LOH detected for the region.

- 10 All five normal breast epithelial cell cultures expressed high levels of Brush-1 mRNA. In contrast, 6 of 13 breast cancer cell lines produced greatly reduced levels of Brush-1 mRNA. It appears that the Brush-1 gene shows no expression in five of these  
 15 cell lines and only at very low levels for DU4475. These low mRNA levels were consistently observed by both RT-PCR and Northern analyses (data not shown). Conversely, RB1 mRNA is expressed in all normal and breast cancer cell lines except DU4475. The Brush-1  
 20 mRNA, therefore, shows much more differential expression in the cancer cell lines than RB1.

- The Brush-1 tumor suppressor gene was detected in formalin fixed tissue section using in situ reverse transcriptase polymerase chain reaction  
 25 (in situ RT PCR). Brush-1 cDNA was synthesized in situ by reverse transcription using a Brush specific oligonucleotide primer. In situ polymerase chain reaction amplification in the presence of digoxigenin-11-dUTP and subsequent binding with an  
 30 antidigoxigenin antibody conjugated to alkaline phosphatase allowed direct visualization. Brush-1 is expressed in the luminal layer of epithelial cells of lobules and ductules in tissue sections from normal reduction mammoplasties (5 patients). In sections of  
 35 invasive carcinoma, the tumor suppressor gene is expressed in about 10% of the invasive tumor cells (7

patients). In cases of invasive carcinoma that contain a loss of heterozygosity (LOH) in the 13q13-14 region, no tumor cells express Brush-1. The specificity of the in situ reaction described above was demonstrated by performing a reaction without reverse transcriptase and also eluting the amplified fragments from the sections and detection by agarose gel electrophoresis. These results show that in vivo the Brush-1 gene has the expression pattern expected for a tumor suppressor gene. For immunodetection of Brush-1 message in tissue from reduction mamplasties, archival formalin/alcohol fixed, paraffin embedded sections were subjected to RT in situ PCR. Lobules and ducts from the same section with no RT step and with the RT step were compared. The results showed that Brush-1 message is expressed at high levels in epithelial cells, and the sections with no RT step are negative.

Immunodetection of Brush-1 message in tumor cells displayed a loss of heterozygosity in the 13q13-14q region, proximal to the retinoblastoma gene. Archival formalin fixed, paraffin embedded sections were subjected to RT in situ PCR and an area of invasive tumor cells was examined having a section with RT step. The results show tumors bearing an LOH at 13q 13-14 do not express Brush-1 message.

Since in situ RT PCR is applicable to any in vivo system and is capable of detecting low copy mRNAs, it is useful in studying tumor suppressor gene expression in vivo in rare and difficult to obtain cells. Therefore, molecules may be investigated for which there are no antibodies available, as is the case with Brush-1. Since the method is based on the incorporation of digoxigenin-11-dUTP during amplification and then immunodetection, it is rapid,

- 13 -

requiring less than two days, and there is essentially no non-specific binding. Moreover, less than 20 copies of mRNA per cell can be detected. See Nuovo, GJ et al. Am J Pathol 1991, 189:847; Heniford, BW et al. NAR 1993, 21:3159. Therefore, this technique is well suited to the study of single cells obtained from nipple aspirates. It is also well suited for the study of heterogeneous cell populations where only a few cell express the gene of interest. Such a study was done on peripheral blood cell from patients with HIV where it was shown for the first time by in situ RT-PCR that some leukocytes harbor the HIV virus (Nuovo, GJ et al. J. of acquired Immune Deficiency Syndromes, 1994 7:916).

15           The Brush-1 cDNA probe is a 4.3 kb sequence assembled from Brush-1 cDNA clone fragments. The correct 5'-3' orientation for each fragment was determined by Northern hybridization of separate single-stranded riboprobes complementary to each of the cDNA strands. Only one orientation hybridized to the 4.7 kb mRNA. SEQ ID NO:1 is the sequence for this cDNA probe. Sequence analysis revealed no significant homology to any known sequences in the Genbank. A longer cDNA sequence (4.3 kb) which hybridizes to the mRNA is SEQ ID NO:2 assembled from fragments used to assemble SEQ ID NO:1 and additional clone fragments. SEQ ID NO:1 is contained within SEQ ID NO:2 and begins at position 818 in SEQ ID NO:2.

30           The relationship of Brush-1 to RB1 was first suggested by preliminary mapping of the gene to chromosome 13. The cytological position of Brush-1 relative to RB-1 was done by FISH analysis. Brush-1 is localized to a single position at 13q12-q13, proximal to RB1. Previous studies by Lundberg, C., et al., Proc. Natl. Acad. Sci. USA 84: 2372-2376

- 14 -

(1987) and Devilee, p., et al., *Genomics* 5: 554-560 (1989) found that many breast cancers showed LOH over a large region which included 13q12-13 and that in one primary breast tumor the LOH on chromosome 13q included 13q12-q13 but did not include RB1. Since Brush-1 is proximal to RB1, and Brush-1 is often lost in breast cancer cell lines, it is a useful diagnostic tool for identifying primary breast tumors.

10           The LOH at D13S219, located at 13q13, was surveyed for and compared to LOH found at the RBI gene. In one survey of 108 primary breast tumors it was found that LOH at the RBI gene was 45%. Another survey of 76 tumors from the same population gave 42% LOH for D13S219. In all cases where the samples were informative for both RBI and D13S219, the results were identical for LOH. A selection of these tumors were examined for expression of the Brush-1 and RB1 mRNA (Table 1). Four tumors with no LOH in this region demonstrated expression for both Brush-1 and RB1. In contrast, four tumors which clearly demonstrated LOH at both D13S219 and RB1, all showed decreased expression for Brush-1 while maintaining normal levels of expression for RB1. This differential loss of Brush-1 expression, therefore, is manifest in both breast cancer cell lines and primary breast tumors.

          The Brush-1 mRNA is thus useful as a diagnostic marker for breast cancer. The Brush-1 cdna probe, or substantially identical sequences, that is, sequences having 90% or greater homology with the Brush-1 cdna probe, may be used to detect the presence of this marker in breast tissue or cell samples by generally applied molecular techniques known to those of ordinary skill in the art, such as



- 15 -

Northern analysis and *in situ* hybridization. By comparison of the differential amounts of mRNA in the suspected tumor cells and normal cells, the likelihood of the presence of breast cancer can be  
5 ascertained. In addition, the probe may be used in the design and manufacture of new drugs for the treatment of breast cancer. The Brush-1 RNA (or DNA) may be used as gene therapy agents to provide missing tumor suppressor function where it is naturally  
10 lacking.

We also noted from a BLAST search that the 5' of Brush-1 from the start of the cDNA is 98% homologous (in anti-sense relationship) to the actin binding protein ABP-280 (8360bp; see J.Cell Biol.  
15 111(3):1089-105(1990)). This suggests that Brush-1 could act as antisense RNA to block RNA translation for ABP-280 which is important to cell growth and motility.

In addition, lack of or abnormally low  
20 expression of a Brush-1 gene or the presence of a mutant Brush-1 gene in a patient may predispose that individual to breast or other types of cancer. Such a familial breast cancer gene, BRCA1, had been previously localized to chromosome 17 and the target  
25 gene has now been identified [Miki et al., 1994, Science 266:66-71; Futreal et al., 1994, Science 266:120-122]. Recently, a second familial breast cancer gene, BRCA2, was localized to chromosome 13q12-13 [Wooster et al., 1994, Science 265:2088-  
30 2090]. Furthermore, the BRCA2 gene was most closely linked to the polymorphic microsatellite repeat marker D13S260. Yeast Artificial Chromosomes (YACs) isolated with the D13S260 markers were tested for the presence of the Brush-1 gene. Of eight YACs tested,  
35 two were conclusively shown to contain the Brush-1

gene. Therefore, this second familial breast cancer gene is in the same chromosomal location (13q12-13) as Brush-1 and Brush-1 is contained in the chromosomal segment showing the strongest linkage to  
5 BRCA2.

The nucleotide sequences of this invention used for diagnostic applications ~~may be the~~ entire sequence of the gene or may be ~~fragments thereof~~ based on restriction enzyme digestion (~~which~~ fragments may be  
10 all or part of the open reading frames) untranslated regions, intermediate coding regions, and fragments and combinations thereof. The minimum size single-stranded fragment will be at least 20 bases and usually at least 50 bases and may be 100 bases or  
15 more. The sequence may be obtained as a fragment or be synthesized.

The fragments can be used in a wide variety of ways, depending upon their size, their natural function, the use for which they are desired, and the  
20 degree to which they can be manipulated to modify their function. Thus, sequences of at least 20 bases, more usually at least 50 bases, and usually not exceeding about 1000 bases, more usually not exceeding about 500 bases, may serve as probes for  
25 detection of the presence of Brush-1 in a host tissue, including the genome, or in a physiological fluid, such as blood, lymph, saliva, spinal fluid, or the like. These sequences may include coding and/or non-coding sequences.

30 Where the nucleotide sequences are used for duplex formation, hybridization, or annealing, for example, for diagnosis or monitoring of the presence of the Brush-1 in vivo or in vitro, complete base pairing will not be required. One or more mismatches

- 17 -

are permissible. To ensure that the presence of one or a few, usually not more than three, mismatches still allows for stable duplexes under the predetermined stringency of hybridizing or annealing conditions, probes will normally be greater than 20 bases, preferably at least about 50 bases or more.

The method of detection will involve duplex formation by annealing or hybridization of an oligonucleotide probe, either labeled or unlabeled, depending upon the nature detection system, with the DNA or RNA of host tissue suspected of harboring Brush-1. A physiological sample may include tissue, blood, serum, etc. Particularly, blood samples will be taken, more particularly blood samples containing peripheral mononuclear cells, which may be lysed and the DNA or RNA isolated in accordance with known techniques.

The sample polynucleotide mixture obtained from the human host can be bound to a support or may be used in solution depending upon the nature of the protocol. The well-established Southern technique [(1975) J. Mol. Biol. 98:503] may be employed with denatured DNA, by binding the single-stranded fragments to a nitrocellulose filter. Alternatively, RNA can be blotted on nitrocellulose following the procedure described by Thomas, (1980) Proc. Natl Acad. Sci. (USA) 77:5201. Desirably, the fragments will be electrophoresed prior to binding to a support, so as to be able to select for various sized fractions. Other techniques may also be used such as described in Meinkoth & Wahl, (1984) Anal. Biochem. 138:267-284.

The oligonucleotide probe may be DNA or RNA, usually DNA. The oligonucleotide sequence may

-18-

be prepared synthetically or in vivo by cloning, where the complementary sequence may then be excised from the cloning vehicle or retained with the cloning vehicle. Various cloning vehicles are available, such as pBR322, M13, Charon 4A, or the like, desirably a single-stranded vehicle, such as M13.

As indicated, the oligonucleotide probe may be labeled or unlabeled. A wide variety of techniques exist for labeling DNA and RNA. As illustrative of such techniques, is radiolabeling using nick translation, tailing with terminal deoxytransferase, or the like, where the bases which are employed carry radioactive  $<^{32}> P$ . Alternatively, radioactive nucleotides can be employed where carbon, nitrogen or other radioactive atoms may be part of the nucleoside structure. Other labels which may be used include fluorophores, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, or the like. Alternatively, instead of having a label which provides for a detectable signal by itself or in conjunction with other reactive agents, ligands can be used to which receptors bind, where the receptors are labeled such as with the above-indicated labels, which labels provide detectable signals by themselves or in conjunction with other reagents See, e.g., Leary et al. (1983) Proc Natl. Acad. Sci. (USA) 80:4045-4049; Cosstick et al. (1984) Nucleic Acids Res. 12:1791-1810.

The oligonucleotide probes are hybridized with the denatured human host nucleic acid, substantially intact or fragmented, or fractions thereof, under conditions of predetermined stringency. The stringency will depend upon the size and composition of the probe, the degree of mismatching, and the like. Usually, an organic

-19-

solvent such as formamide will be present in from about 30 to 60 vol percent, more usually from about 40 to 50 vol percent, with salt concentration from 0.5 to 1M. Temperatures will generally range from about 30° C to 65° C., more usually from about 35° C. to 50° C. The times for duplex formation may be varied widely, although minimum times will usually be at least about one hour and not more than about 72 hours, the time being selected in accordance with the amount of DNA or RNA available, the proportion of DNA or RNA as compared to total DNA or RNA, or the like. Stringency may also be modified by ionic strength and temperature. The hybridization and annealing can be carried out in two stages: a first stage in a hybridization medium; and, a second stage, involving washings at a higher stringency, by varying either or both temperature and ionic strength.

As understood in the art, the term "stringent hybridization conditions" as used herein refers to hybridization conditions which allow for closely related nucleic acid sequences to duplex (e.g., greater than about 90% homology), but not unrelated sequences. The appropriate conditions can be established by routine procedures, such as running Southern hybridization at increasing stringency until only related species are resolved and the background and/or control hybridization has disappeared (i.e., selective hybridization).

Nucleotide probes may be prepared employing reverse transcriptase using primers, e.g., random primers or specific primers. The cDNA may be prepared employing a radioactive label, e.g.,  $^{32}$ P, present with one or more of the dNTPs. Reverse transcription will provide various sized fragments depending on the primers, the efficiency of

-20-

transcription, the integrity of the RNA, and the like. The resulting cDNA sequences may be cloned, separated and used for detection of the presence of *Brush-1* in the human genome.

- 5           Using specific primers of 10 to 20 bases, or more, *Brush-1* may be reverse transcribed and the resulting ss DNA used as a probe specific for the region which hybridized to the primer. By employing one or more radionucleotide-labeled bases, the probes  
10 will be radiolabeled to provide a detectable signal. Alternatively, modified bases may be employed which will be randomly incorporated into the probe and may be used to provide for a detectable signal. For example, biotin-modified bases may be employed. The  
15 resulting biotin-containing probe may then be used in conjunction with labeled avidin to provide for a detectable signal upon hybridization and duplex formation.

- The *Brush-1* sequence may also be used therapeutically  
20 through gene therapy on subjects identified as having a genetically aberrant *Brush-1* gene. The subjects will then have normal *Brush-1* DNA and the ability to utilize its tumor-suppressing activity. For example *Brush-1* DNA may be injected into subject after being  
25 based to an appropriate vector, such as viral vectors, liposomes and other vectors known in the art.

-21-

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: SCHOTT, D.

(ii) TITLE OF INVENTION: CDNA PROBE FOR BREAST  
5 CANCER DIAGNOSIS  
AND TREATMENT

(iii) NUMBER OF SEQUENCES: 2

(iv) CORRESPONDENCE ADDRESS:

10 (A) ADDRESSEE: REGINALD J. SUYAT, ESQ.  
(B) STREET: 333 BUSH STREET  
(C) CITY: SAN FRANCISCO  
(D) STATE: CALIFORNIA  
(E) COUNTRY: USA  
15 (F) ZIP: 94104-2878

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
20 (D) SOFTWARE: PatentIn Release #1.0,  
Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US  
(B) FILING DATE:  
25 (C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/160,088  
(B) FILING DATE: 30-NOV-1993

(vii) PRIOR APPLICATION DATA:

30 (A) APPLICATION NUMBER: US 08/314,598  
(B) FILING DATE: 27-SEP-1994

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: SUYAT, REGINALD J.  
(B) REGISTRATION NUMBER: 28,172  
35 (C) REFERENCE/DOCKET NUMBER: 11561-0026

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 415-772-6432  
(B) TELEFAX: 415-772-6268

## (2) INFORMATION FOR SEQ ID NO:1:

40 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 3542 base pairs

-22-

(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
CTGCTGTCTG GGATGGTGCA GCTCCACAGT TTTCTCTAAT
GGTGTTCAGG TACACTGAAA      60

TTAGGAATTT TTAATATTTT AACACATTAC TTTGTTACAA
AAAAACTTCT CACTTTGAAT      120

10 GCATGTTTTT TCTCATGAAA CTTTAAATAT TCCCTGAGCT
TTTCTCCCCT CAAATTTCTA      180

AAACTTTCTG TCCTTAGTGT CAGTAGAAAA AAAAGTCCAA
TAGACATATT TGTCGTTTA      240

TCTTTAATTT GGAGCCAGCA AAAGGATGTG ATTCTGAACC
15 ACGTGTTGTG TCTGCAGGAA      300

TTCAACTGAA AAAGGTGCAG GAGCAGCGGG AGCAGGAGGC
CAAGCGGGAG CCAGTGGGGA      360

ATGACGTGGC CACGATCCTG TCCCGGCGCA TTGCCGTGGA
GTACAGCGAC TCTGACGACG      420

20 ACTCAGAGTT CGACGAGAAC GACTGGTCCG ACTGAGCAAA
GGCCGGCGGA GAGGCCGCGT      480

GTGGGAGCGT GTTGAAGATT TTAAGTGGTC TCTACACCCA
AATAGTGGTA TTCTAATCCC      540

GTAGCATAGC ACCTTTTGTA TAAACAATGT GATATTGCTT
25 CTGCACATCC AAAAATTCTG      600

GGTCTTTTCA GTATTTACTG TGTAATACTT AAGTGCCACT
AAACATAGCA AATTGTGCTG      660

CACATGAGGA AATAGGCTGT CACTATCACA TTGTCCTGAA
AACAGCATCT GCTTTCCTCT      720

30 TGGCCATGAG AGTATTTAGT GCAGTTTGGG TTTACTCTTA
CTGATCAATA TAACTCTGCA      780

GACTTGCTGT GTGTTTGTGA AGCTGCCTGG TGTTAGGTCT
CTGCAAGACT AATGACTATG      840

TCAGAGTGAT GTCTTCCAAC CAGTAAGTGA TATTGTTTCA
35 CCGCTTTGGT TTTTCCTTTT      900
```



-23-

	GTTTTTTTAA	AGGATGTGTT	TCTGAATAAG	TTGGTTTTAG	
	AGGGAAAGGT	TCAACAAACA	960		
	GGGAGAATCC	AGTGTTCCTG	CTTTCAGTTT	CTTGGCTTGG	
	TAGCCTCTGA	GTGAATCTGA	1020		
5	TGCTCTGCTG	AATAATTTCA	TTACCTCTGC	ACATGCCTGT	
	CAAATATGAA	ATTGGAAGGG	1080		
	CCCTTTTTCAG	GCTGGGTTC	CTGTGGGCAT	TTGCTTAGTA	
	AATGCCTGTT	GATGGTTTTT	1140		
	GCAAGAGAAT	TCAGCAGCTC	AACAGTAATG	AAAGTGAAGA	
10	ACAGAGTCCA	TTTTCCTTCC	1200		
	TGGGGCCATT	GGGGATGACA	CTCAAGATAC	TTGCCAGTCT	
	CTCCAGTGTG	GGCACCAGCC	1260		
	GGCCAGAACA	GATGCGAGCA	GTCCATGACT	CTGGGAGCTA	
	CACCGCTGAG	CTGGGCAGAG	1320		
15	CTGCGGCACA	GGGCCTGGGC	TGCAAAGGTG	CCCTGCTCCT	
	TTAGTTTCCT	GACACCTGTG	1380		
	TCCTGAGTGA	GCCGCAGGAG	TTCTTAGCTC	CTCAGCGAGC	
	AACAGAGAGC	ACTTTAGATG	1440		
	GCACCTTTCA	CCACTTGGTC	AGAATTTTAA	AAGCTTAGGT	
20	TTAGGTGAAA	GTAGATATTG	1500		
	ACAGCTATTC	ACCTTTCACG	GTGCTGGGGC	CAGATTAGGG	
	ATCACTCCCG	TGAGGAGGGC	1560		
	CTTCACCCTG	TTCTAGAAGC	ACATGGTTGT	CCTCCTGTTG	
	TTGGCACATT	AAATGATAAA	1620		
25	AAGCACCTCA	TGAGATTCCC	TTGATCAGCC	CTGCAGCTGT	
	AGTACAGTGC	TGTGCCCTCA	1680		
	CCTCCACCCT	TCCTGTTGTT	CCCACGTGGG	CAATACCAGG	
	GACCCATGGG	GAAACTCAAG	1740		
	AATGACAGCT	TCTATATTTT	GTAATTCTGG	ATGAAAGATA	
30	ACTGTGTTGA	ACAAACAGGT	1800		
	GCTCCAGGCT	TTGATTATAG	ATACGACTTC	AAAAATATGC	
	TAAGACGCTT	GACTTATTAA	1860		
	GGACTTTAAC	CTACTCAACA	GTATTTTATA	TCCATTGTGG	
	TTAGTTACTC	AGTTATGTTG	1920		
35	AGAAGAATCT	GGAGCTAAAA	GCAGAGATGT	TTGAGGTGAC	
	GGTAGGAATG	TGAGCAGGAT	1980		

-24-

	GGTGATGGGG	GTTTTTGTTA	AAATGCATCT	GAGCAAGTCA
	GCCAGCCCCG	AAGTCCCCTC	2040	
	AGTGTGTGTG	TCTCGAGTGG	CTACCTGTTG	GGCTTGTGGG
	CAGTGATTGT	ACAGAGCCTG	2100	
5	TCCATTGGGT	GCAGTCATGT	AGATCTGAAG	CCCTGAAAAG
	CCTCATGTCT	GCATCCCCTT	2160	
	TCCAAGGCTG	CTTCCCTGGT	GTGTCTGTTC	TCTCCTCTGT
	CCCAGGTGCT	GGGAGCGTCC	2220	
10	TCTTCAGCGT	CTTTTCCTAG	AGCTGGTCAC	CACTAGGCTG
	TC...CTATAAA	TTCCTTGAAT	2280	
	ATAAGTAACA	GTTATTAATG	AACTTCTAAA	TTTCTAATTT
	CTCTCTCTCT	CTCTCTTTTT	2340	
	TTTTTTTTTTG	TTGTTGTAA	AAAGGGCCTA	CTACATTGGC
	GCTATTCTTA	GGACTTCTGC	2400	
15	AACTTTTAAA	GTCTTACTTG	TCTTTCTTGT	TGCTTTTGTA
	TTAGGAGTTC	CCCGTGTGGG	2460	
	TCTAGAACTC	CCCTTTGGTA	ATGCTTCTTT	GTTTTTTTAT
	GGCCCTTCTG	TTCTCAGGAT	2520	
20	GGAGAGAACA	CAGAAGCTAC	TATCCATGTC	AGGATTTATT
	CTATTTATAT	CTTATTACAA	2580	
	TAAAATTAGT	GGCACTTTAT	TCATAAATAT	TCATGAGCCT
	GTTAATTGTT	AGTTGTCTTC	2640	
	CTGTAGCTGA	ATCAACAAGT	TATTTTCAAC	TCAATTTTAT
	GACTTGCGAA	AAAGCTTTTG	2700	
25	CCCTGTTGTG	TACCATAACA	TTTAAAAGAA	TGGAAAATGA
	CTGAAATCCA	ATTTAGATTA	2760	
	TTTTTAGAGT	ATTTTCCAG	CAAATTCAAT	TTATTCTGAA
	ATTTAAATCC	AGATCTTTTC	2820	
30	TAATATGGTA	TTACAATGAA	AAGAATAAAG	AGAAGATTTG
	AATTTTCAGT	TTCATTTTCA	2880	
	AAAACATTTT	ACCAAAACAA	ATGGAGAAGA	AACATCCAAA
	AGCACATTTC	ATTTCTCCAA	2940	
	ACTTTGTGTT	TTAAATTATA	GTTATAAATT	GTAAGGTAAT
	TTTAAATTGT	CCCTCGTATT	3000	
35	ATTTCTCCAC	GTCTGTTTTA	GTTTAATGTC	TCCTAAGCTT
	TTCTCTCATA	GCGTAGACCT	3060	

-25-

AGGGAAGGGA TGGGAAGATT GCCCAGTCCC CGATGGCTGC  
 GCACACAGGA GCGGCGCGAC 3120  
  
 GACAAGGCAA GTGAGTTTGC ACTGTCAGCC CCAGACCGTA  
 AGCTTGGCTA CACTGATGTT 3180  
  
 5 TTTCTTTACT AAGGATACTA TTCAAAAATT AACATTTTCA  
 TCTCAGTAAG TTTTGTAGAAC 3240  
  
 ATCAAAATGT TTTCTGAGCT CCAAGTGGCT AGGTTGTAA  
 AGTTTTATAA TAATTTGCAA 3300  
  
 TTAATAATACA TGATACATAT TAATCCATTA AAGACTAGTG  
 10 GGAATGTATC AGCTCAGTA 3360  
  
 GCAAGTAATT TTTGTTTTAT AAATCATAGT ATCTGTCATC  
 TTGCAGTATT ACCAATGCTG 3420  
  
 TTGTAAATTG AATTTAAAGT GGTATTAAAA AAAACTGTTA  
 AACAATTTT ATCTGTTTGT 3480  
  
 15 ATATCTTACT ATAGATTATG TACAAGTAAC ATCTAAATAA  
 AATTACACTT TTAACCCTAA 3540  
  
 AA  
 3542

## (2) INFORMATION FOR SEQ ID NO:2:

- 20 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 4359 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear  
  
 25 (ii) MOLECULE TYPE: cDNA to mRNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GGCTGGCACT CCAGCTTCAG CTCTCTCCAG GCCAGGGCCC  
 CCAGCTCGGA CCTTGTGGGC 60  
  
 TCCCCCTTCC CCTAGGGGCC CCACGATGAA CTATTTTAGG  
 30 GGTAAAGGGA CATTATATGC 120  
  
 CATTCACTCT CAAATGGTCC AGAGAAAAGT GTCTGTGTCT  
 GTCTGTGTAA AGATGATAGG 180  
  
 GGAAGATTGG GAAATAAATG TGGTCAGATG TTAGCAGTTG  
 GGAATCCAA GTATATGGGA 240  
  
 35 ATGTTTTTCT GCTGGTCTCA TAGCTGTTCT GTAAATCTGA  
 AATTATTTCA AAACAGTTAA 300

-26-

	AAAATGAATG	GATACCATCT	TGGGCAACAT	TGCAAGACTC	
	TATCTCTACA	AAAAAGAAAA	360		
	TACAAAATTT	AACCGTGCAT	GGTGGCGTGC	GCCGGTGGTT	
	CCAGCTACTC	AGGAGGCTGA	420		
5	GGTGGGAGGA	TTGCTTGAGC	CCAGGAGGTC	GAGGCTGCAG	
	TGAGCCATGA	TCGTAACACT	480		
	GCACTCCAGC	CTGGGTCACA	GAGTGAGACC	CAATCTCAAA	
	AAAAAAAAAA	ATGGATAAAC	540		
10	ATTAAATCAT	CAAATATCTT	ACTTTGTTAC	TAAGCTAGAA	
	AGTAGATGAT	TGTATTTTAT	600		
	GTTTGTTTCC	ACAGTAATTG	TTGAAATAAA	GGTTTCTCAG	
	TTACTTCTTG	GGTTAGCTGA	660		
	GAGTGAGTAG	CATAGAACAC	TGTTTCCAAG	GCTCTGGATG	
	CTGTTGCTGC	CTAGTAGATG	720		
15	TCCTGTGGTG	ATAGAAATGC	TCCAGCCTGC	AGCGTCCCAG	
	AGAGTAGCCA	CTAGCCACAT	780		
	GTCAGTTCAT	GCTTTTAAGG	CTATATGTGC	CTAGTGGCTG	
	CTGTCTGGGA	TGGTGCAGCT	840		
20	CCACAGTTTT	CTCTAATGGT	G TTCAGGTAC	ACTGAAATTA	
	GGAATTTTTA	ATATTTTAAC	900		
	ACATTACTTT	GTTACAAAAA	AACTTCTCAC	TTTGAATGCA	
	TGTTTTTTCT	CATGAAACTT	960		
	TTAATATTCC	CTGAGCTTTT	CTCCCCTCAA	ATTTCTAAAA	
	CTTCTGTGCC	TTAGTGTGAG	1020		
25	TAGAAAAAAA	AGTCCAATAG	ACATATTTGT	TCGTTTATCT	
	TTAATTTGGA	GCCAGCAAAA	1080		
	GGATGTGATT	CTGAACCACG	TGTTGTGTCT	GCAGGAATTC	
	AACTGAAAAA	GGTGCAGGAG	1140		
30	CAGCGGGAGC	AGGAGGCCAA	GCGGGAGCCA	GTGGGGAATG	
	ACGTGGCCAC	GATCCTGTCC	1200		
	CGGCGCATTG	CCGTGGAGTA	CAGCGACTCT	GACGACGACT	
	CAGAGTTCGA	CGAGAACGAC	1260		
	TGGTCCGACT	GAGCAAAGGC	CGGCGGAGAG	GCCGCGTG TG	
	GGAGCGTGTT	GAAGATTTTA	1320		
35	AGTGGTCTCT	ACACCCAAAT	AGTGGTATTC	TAATCCCGTA	
	GCATAGCACC	TTTTGTATAA	1380		

-27-

	ACAATGTGAT	ATTGCTTCTG	CACATCCAAA	AATTCTGGGT	
	CTTTTCAGTA	TTTACTGTGT	1440		
	AATACTTAAG	TGCCACTAAA	CATAGCAAAT	TGTGCTGCAC	
	ATGAGGAAAT	AGGCTGTCAC	1500		
5	TATCACATTG	TCCTGAAAAC	AGCATCTGCT	TTCCTCTTGG	
	CCATGAGAGT	ATTTAGTGCA	1560		
	GTTTGGGTTT	ACTCTTACTG	ATCAATATAA	CTCTGCAGAC	
	TTGCTGTGTG	TTTGTGAAGC	1620		
10	TGCCTGGTGT	TAGGTCTCTG	CAAGACTAAT	GAATATGTCA	
	GAGTGATGTC	TTCCAACCAG	1680		
	TAAGTGATAT	TGTTTCACCG	CTTTGGTTTT	TCCTTTTGTT	
	TTTTTAAAGG	ATGTGTTTCT	1740		
	GAATAAGTTG	GTTTTAGAGG	GAAAGGTTCA	ACAAACAGGG	
	AGAATCCAGT	GTTTCTGCTT	1800		
15	TCAGTTTCTT	GGCTTGGTAG	CCTCTGAGTG	AATCTGATGC	
	TCTGCTGAAT	AATTTCATTA	1860		
	CCTCTGCACA	TGCCTGTCAA	ATATGAAATT	GGAAGGGCCC	
	TTTTCAGGCT	GGGTTCCCTG	1920		
20	TGGGCATTTG	CTTAGTAAAT	GCCTGTTGAT	GGTTTTTGCA	
	AGAGAATTCA	GCAGCTCAAC	1980		
	AGTAATGAAA	GTGAAGAACA	GAGTCCATTT	TCCTTCCTGG	
	GGCCATTGGG	GATGACACTC	2040		
	AAGATACTTG	CCAGTCTCTC	CAGTGTGGGC	ACCAGCCGGC	
	CAGAACAGAT	GCGAGCAGTC	2100		
25	CATGACTCTG	GGAGCTACAC	CGCTGAGCTG	GGCAGAGCTG	
	CGGCACAGGG	CCTGGGCTGC	2160		
	AAAGGTGCCC	TGCTCCTTTA	GTTTCCTGAC	ACCTGTGTCC	
	TGAGTGAGCC	GCAGGAGTTC	2220		
30	TTAGCTCCTC	AGCGAGCAAC	AGAGAGCACT	TTAGATGGCA	
	CCTTTCACCA	CTTGGTCAGA	2280		
	ATTTTAAAAG	CTTAGGTTTA	GGTGAAAAGTA	GATATTGACA	
	GCTATTCACC	TTTCACGGTG	2340		
	CTGGGGCCAG	ATTAGGGATC	ACTCCCGTGA	GGAGGGCCTT	
	CACCCTGTTC	TAGAAGCACA	2400		
35	TGGTTGTCCT	CCTGTTGTTG	GCACATTAAA	TGATAAAAAG	
	CACCTCATGA	GATTCCCTTG	2460		

-28-

	ATCAGCCCTG	CAGCTGTAGT	ACAGTGCTGT	GCCCTCACCT
	CCACCCTTCC	TGTTGTTCCC	2520	
	ACGTGGGCAA	TACCAGGGAC	CCATGGGGAA	ACTCAAGAAT
	GACAGCTTCT	ATATTTTGTA	2580	
5	ATTCTGGATG	AAAGATAACT	GTGTTGAACA	AACAGGTGCT
	CCAGGCTTTG	ATTATAGATA	2640	
	CGACTTCAAA	AATATGCTAA	GACGCTTGAC	TTATTAAGGA
	CTTTAACCTA	CTCAACAGTA	2700	
10	TTTCATATCC	ATTGTGGTTA	GTTACTCAGT	TATGTTGAGA
	AGAATCTGGA	GCTAAAAGCA	2760	
	GAGATGTTTG	AGGTGACGGT	AGGAATGTGA	GCAGGATGGT
	GATGGGGGTT	TTTGTAAAA	2820	
	TGCATCTGAG	CAAGTCAGCC	AGCCCCGAAG	TCCCCCTCAGT
	GTGTGTGTCT	CGAGTGGCTA	2880	
15	CCTGTTGGGC	TTGTGGGCAG	TGATTGTACA	GAGCCTGTCC
	ATTGGGTGCA	GTCATGTAGA	2940	
	TCTGAAGCCC	TGAAAAGCCT	CATGTCTGCA	TCCCCCTTCC
	AAGGCTGCTT	CCCTGGTGTG	3000	
20	TCTGTTCTCT	CCTCTGTCCC	AGGTGCTGGG	AGCGTCCTCT
	TCAGCGTCTT	TTCCTAGAGC	3060	
	TGGTCACCAC	TAGGCTGTCA	CTATAAATTC	CTTGAATATA
	AGTAACAGTT	ATTAATGAAC	3120	
	TTCTAAATTT	CTAATTTCTC	TCTCTCTCTC	TCTTTTTTTT
	TTTTTTGTTG	TTGTTAAAA	3180	
25	GGGCCTACTA	CATTGGCGCT	ATTCTTAGGA	CTTCTGCAAC
	TTTTAAAGTC	TACTTGTCT	3240	
	TTCTTGTTGC	TTTTGTATTA	GGAGTTCCCC	GTGTGGGTCT
	AGAACTCCCC	TTGGTAATG	3300	
30	CTTCTTTGTT	TTTTTATGGC	CCTTCTGTTC	TCAGGATGGA
	GAGAACACAG	AAGCTACTAT	3360	
	CCATGTCAGG	ATTTATTCTA	TTTATATCTT	ATTACAATAA
	AATTAGTGGC	ACTTTATTCA	3420	
	TAAATATTCA	TGAGCCTGTT	AATTGTTAGT	TGTCTTCCTG
	TAGCTGAATC	AACAAGTTAT	3480	
35	TTTCAACTCA	ATTTTATGAC	TTGCGAAAAA	GCTTTTGCCC
	TGTTGTGTAC	CATAACATT	3540	

-29-

	AAAAGAATGG	AAAATGACTG	AAATCCAATT	TAGATTATTT	
	TTAGAGTATT	TTTCCAGCAA	3600		
	ATTCAATTTA	TTCTGAAATT	TAAATCCAGA	TCTTTTCTAA	
	TATGGTATTA	CAATGAAAAG	3660		
5	AATAAAGAGA	AGATTTGAAT	TTTCAGTTTC	ATTTTCAAAA	
	ACTATTTACC	AAAACAAATG	3720		
	GAGAAGAAAC	ATCCAAAAGC	ACATTTTCATT	TCTCCAAACT	
	TTGTGTTTTA	AATTATAGTT	3780		
10	ATAAATTGTA	AGGTAATTTT	AAATTGTCCC	TCGTATTATT	
	TCTCCACGTC	TGTTTTAGTT	3840		
	TAATGTCTCC	TAAGCTTTTC	TCTCATAGCG	TAGACCTAGG	
	CAAGGGATGG	GAAGATTGCC	3900		
	CAGTCCCCGA	TGGCTGCGCA	CACAGGAGGC	GGCGGACGAC	
	AAGGCAAGTG	AGTTTGCACT	3960		
15	GTCAGCCCCA	GACCGTAAGC	TTGGCTACAC	TGATGTTTTT	
	CTTTACTAAG	GATACTATTC	4020		
	AAAAATTAAC	ATTTTCATCT	CAGTAAGTTT	TTAGAACATC	
	AAAATGTTTT	CTGAGCTCCA	4080		
20	AGTGGCTAGG	TTGTAAAAGT	TTTATAATAA	TTTGCAATTA	
	AAATACATGA	TACATATTAA	4140		
	TCCATTAAAG	ACTAGTGGGA	ATGTATCAGC	CAGAGTAGCA	
	AGTAATTTTT	GTTTTATAAA	4200		
	TCATAGTATC	TGTCATCTTG	CAGTATTACC	AATGCTGTTG	
	TAAATTGAAT	TTAAAGTGGT	4260		
25	ATTAAAAAAA	ACTGTAAAC	AATTTTATC	TGTTTGTATA	
	TCTTACTATA	GATTATGTAC	4320		
	AAGTAACATC	TAAATAAAAT	TACACTTTTA	ACCCTAAAA	
		4359			

-30-

## WHAT IS CLAIMED IS:

1. Isolated DNA comprising a nucleotide sequence substantially identical to SEQ ID NO:1.
2. Isolated DNA comprising a nucleotide sequence  
5 substantially identical to SEQ ID NO:2.
3. A diagnostic agent for detecting tumors and pre-malignant cells in host tissue or cells comprising at least one probe selected from the group consisting of a DNA sequence substantially identical to SEQ ID  
10 NO:2, its complementary DNA sequence, an RNA sequence substantially identical to the RNA complement of SEQ ID NO:2, the complement of said RNA complement, and fragments of said sequences; and a marker on said probe.
- 15 4. A pharmaceutical composition for providing or enhancing the tumor-suppressing ability of a subject comprising a therapeutically effective amount of mRNA, cDNA of said mRNA or DNA sequences of genomic DNA of BRUSH-1, and a pharmaceutically acceptable  
20 carrier.
5. A diagnostic agent for detecting tumors and pre-malignant cells in host tissue or cells comprising at least one probe selected from the group consisting of a DNA sequence substantially identical to SEQ ID  
25 NO:1, its complementary DNA sequence, an RNA sequence substantially identical to the RNA complement of SEQ ID NO:1, the complement of said RNA complement, and fragments of said sequences, and a marker on said probe.



-31-

6. A diagnostic method for detecting the presence of breast tumors or pre-malignant breast cells in a subject comprising the steps of

- (a) contacting a library containing mRNA  
5 derived from tissue or cells from said subject with one or more labelled probes, said probes comprising DNA segments of SEQ NO:1 or SEQ NO:2;
- (b) separating the probes which hybridize with mRNA from said library;
- 10 (c) identifying the mRNA sequences from step (b) and determining if said sequences define a normal amount of normal BRUSH-1 gene in said subject.

7. A therapeutic method for treating tumors or pre-malignant cells in a subject comprising the steps of  
15 introducing into a subject known or suspected of having tumors, an agent comprising RNA or DNA or selected from the group consisting of mRNA, cDNA and genomic DNA of BRUSH-1, which enables said subject or augments the ability of said subject to suppress  
20 tumor proliferation or growth.

8. A method of providing a subject deficient in a functional BRUSH-1 gene with a functional BRUSH-1 gene, comprising the step of introducing into said subject an agent comprising RNA or DNA selected from  
25 the group consisting of mRNA, cDNA and genomic DNA of BRUSH-1, which enables said subject or augment the ability of said subject to suppress tumor proliferation or growth.

9. A method according to either Claim 7 or 8  
30 wherein said agent comprises a substantially similar variant of said RNA or DNA.

10. A method according to Claim 6 where said probes are labelled.

1 / 3




FIGURE 1

2 / 3




FIGURE 2

3 / 3




FIGURE 3

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US94/13823

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(6) : C07H 21/02, 21/04; C12Q 1/68; A61K 48/00 US CL : 435/6; 536/24.31; 514/44 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/6; 536/24.31; 514/44 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	J. SAMBROOK et al, "MOLECULAR CLONING, A LABORATORY MANUAL" published 1989 by Cold Spring Harbor Laboratory Press (Plainview, New York), pages 7.49-7.52, 7.54, 7.55, and 9.52-9.57, see pages 7.49-7.52, 7.54, 7.55, and 9.52-9.57.	3, 5, 6, 10
Y	The Lancet, Volume 339, issued 21 March 1992, A. A. Gutierrez et al, "Gene Therapy for Cancer", pages 715-721, especially Table IV.	4, 7-9
X,P ----- Y,P	Cancer Research, Volume 54, issued 15 March 1994, D. R. Schott et al, "A Candidate Tumor Suppressor Gene in Human Breast Cancers", pages 1393-1396, especially Table 1 and Figures 2 and 3.	1-3, 5, 6, 10 ----- 4, 7-9
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *&* document member of the same patent family		
Date of the actual completion of the international search 23 FEBRUARY 1995		Date of mailing of the international search report 13 MAR 1995
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer <i>Nathaniel Feys for</i> DAVID SCHREIBER Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US94/13823

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ---- Y	Nature Genetics, Volume 4, issued August 1993, M. D. Adams et al, "Rapid cDNA sequencing (expressed sequence tags) from a directionally cloned human infant brain cDNA library", pages 373-380.	1, 2 ----- 3, 5, 6, 10
X,P ----- Y,P	GenBank, Locus HHEA05L, 06 May 1994.	1, 2 ----- 3-10
X,P ----- Y,P	GenBank Locus HSC1IC112, 04 November 1994.	1,2 ----- 3-10
X,P ----- Y,P	GenBank Locus S69790, 22 September 1994.	1,2 ----- 3-10
X --- Y	GenBank Locus T08945, 03 August 1993.	1,2 ----- 3-10

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US94/13823

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
~~because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:~~
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US94/13823

### B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

GENBANK, GENBANK-NEW, UEMBL, EMBL-NEW, N-GENESEQ, MEDLINE, CA, APS, BIOSIS, WPI  
search terms: gene replacement therapy, hybridization, BRUSH-1, breast cancer, LOH, chromosome 13, DNA, RNA

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claims 1-6 and 10, drawn to an isolated DNA comprising a nucleotide sequence substantially identical to SEQ ID NO:1 or 2; a diagnostic agent for detecting tumors and pre-malignant cells using nucleic acid having the sequence SEQ ID NO:1 or 2 or its complement or fragments of said sequences, a pharmaceutical composition comprising a therapeutically effective amount of BRUSH-1 mRNA, cDNA, or genomic DNA, and a method of diagnosis for detecting breast tumors or pre-malignant cells by determining the quantity of BRUSH-1 mRNA.

Group II, claims 7-9, drawn to a method for introducing into a subject an agent comprising mRNA, cDNA or genomic DNA of BRUSH-1 or a similar variant, which enables said subject or augments the ability of said subject to suppress tumor proliferation or growth.

PCT Rule 13.1 recites the basic principle of unity of invention that an application should relate to only one invention or, if there is more than one invention, that applicant would have a right to include in a single application only those inventions which are so linked as to form a single general inventive concept. According to PCT Rule 13.1, a group of inventions is linked to form a single inventive concept where there is a technical relationship among the inventions that involves at least one common or corresponding special technical feature that defines the contribution which each claimed invention, considered as a whole, makes over the prior art.

The two inventions of this application consist of: Group I, isolated DNA or RNA and a method of using such DNA or RNA for detecting the presence of breast tumors and Group II, a method for introducing into an subject, an agent comprising BRUSH-1 RNA or DNA, which enables the subject or augments the ability of the subject to suppress tumor proliferation and growth. The two inventions are not linked by a special technical feature within the meaning of PCT Rule 13 for the following reasons: The two groups are not linked to the BRUSH-1 DNA by a special technical feature because the methods of the claims share a technical relationship that involves a corresponding special technical feature that does not define the contribution which each claimed invention, considered as a whole, makes over the prior art since detection of a disease by hybridization and treatment of a disorder by gene therapy are well known in the art. Accordingly, the claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept.